AIPPI files intervention in Supreme Court of Canada case

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Cookies Settings

AIPPI files intervention in Supreme Court of Canada case

AIPPI yesterday filed an intervention before the Supreme Court of Canada in the dispute between Apotex and Sanofi-Aventis concerning the drug Plavix. The case concerns the utility requirement in Canadian patent law

The amicus-style brief notes that following the Supreme Court’s decisions in AZT (2002) and VIAGRA (2012), “there has been uncertainty with respect to the precise scope of the utility requirement under Canadian law and in particular the extent to which the utility of a patented invention should be disclosed or supported in the patent specification.”

In AZT, the Court stated that utility must either be demonstrated or be a sound prediction based on information and expertise available at the filing date. In VIAGRA, the Court declined to decide the scope of any disclosure requirement associated with “sound prediction”. The brief states that this “remains an open question in the jurisprudence of this Court, and an area of significant uncertainty in Canadian law”.

Noting that the Court has in previous cases said it is desirable not to apply Canada’s IP laws in a judicial vacuum, AIPPI submits that (1) many jurisdictions have a utility or industrial applicability requirement, (2) for many jurisdictions, the utility or industrial applicability must be indicated in the specification if it is not otherwise obvious, (3) for many jurisdictions, there is no requirement that proof or support be provided in the patent specification, and (4) in a number of jurisdictions “it is relatively rare that utility or industrial applicability is a basis to deny the grant of a patent or for invalidating a granted patent”.

The brief draws on research done by AIPPI over the years and reviews the utility/industrial applicability requirement in the United States, Australia, the EPC and European countries, and Japan. It concludes: “[A] determination on the disclosure requirements in Canada that is, to the extent permissible or practical, consistent with the disclosure requirements of other major jurisdictions can only lead to greater certainty and lower costs for patentees who seek patent protection in Canada.”

Other organisations that have filed briefs in this case include BIOTECanada, Canada’s Research-Based Pharmaceutical Companies, the Centre for Intellectual Property Policy, the Canadian Generic Pharmaceutical Association and FICPI. The case is due to be heard by the Court later this year.

more from across site and SHARED ros bottom lb

More from across our site

The firm has brought in former Weil IP leaders Doug Lumish and Jeff Homrig as it looks to deepen its patent, trade secrets and ITC bench
Bird & Bird helps GSK score a major injunction as the battle to become the UPC’s busiest division tightens, and overall filings reach a new monthly high
CEO Annette Bach explains how the Danish IP consultancy plans to build on its 65% profit growth while keeping external investment off the table for now
Belgian attorneys have revived fax systems to protect clients’ filing rights, while uncertainty over exposed patent data has left firms struggling to answer questions about the breach
In his first interview since leaving Weil Gotshal & Manges, Chris Henry explains why he returned to Latham and how he plans to bolster its tech disputes offering
As GTA VI underlines the extraordinary value of gaming franchises, lawyers at Clifford Chance say investors need to know the IP behind their next deal can deliver the growth they are paying for
As ‘big law’ invests in IP litigation, trial firms are emerging as a valuable source of seasoned courtroom talent
Six hires across the IP spectrum reflect Orrick’s efforts to better serve tech clients across the IP lifecycle
David Stone, partner at White & Case, argues that the government’s planned reforms will modernise and futureproof UK design law, but leave two of the thorniest problems unresolved
Max Scott will join the firm’s IP transactions group in California, becoming the latest Weil IP partner to secure their future
Gift this article